STRO - SUTRO BIOPHARMA, INC.

10.75
0.370   3.442%

Share volume: 40,041
Last Updated: 12-24-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$10.38
0.37
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 12%
Liquidity 34%
Performance 13%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.66%
1 Month
1,150.00%
3 Months
1,140.91%
6 Months
1,234.91%
1 Year
445.69%
2 Year
156.56%
Key data
Stock price
$10.75
P/E Ratio 
0.00
DAY RANGE
$10.20 - $10.83
EPS 
-$2.55
52 WEEK RANGE
$0.52 - $11.09
52 WEEK CHANGE
$445.69
MARKET CAP 
73.618 M
YIELD 
N/A
SHARES OUTSTANDING 
85.135 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
3.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$101,266
AVERAGE 30 VOLUME 
$357,628
Company detail
CEO: William J. Newell
Region: US
Website: sutrobio.com
Employees: 240
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.

Recent news